FSD Pharma Sells Cannara Biotech Stake, Netting More Than $7.7M

FSD Pharma Inc HUGE has netted itself more than $7.7 million through the sale of its 12% equity interest in Cannara Biotech Inc LOVFF to a consortium of that included entities controlled by members of the Cannara board and senior management.

A substantial portion of FSD Pharma's stake in Cannara was subject to a statutory escrow expiring December 2021. Under the terms of the deal, the buyers agreed to acquire FSD Pharma's interest subject to escrow and, as such, assumed all of the associated market risk.

The transaction represents a 670% return on FSD's investment in Cannara.

According to Raza Bokhari, executive co-chairman and CEO of FDS, the transaction was a first step of many to strengthen the company's cash position. FSD Pharma plans on scaling up to $50 million in disposable cash through monetizing their non-cash assets and raising new capital from institutional and institutional grade investors in the U.S. and elsewhere, he said.

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Posted In: CannabisNewsAsset SalesMarkets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...